Table 4.
SABA OTC purchase in the past 12 months in the SABINA III Gulf cluster cohort
|
All (N = 301) |
Primary care physicians (n = 135) | Respiratory specialists (n = 162) | |||||
|---|---|---|---|---|---|---|---|
| Mild asthma (n = 32) |
Moderate-to-severe asthma (n = 103) |
All (n = 135) |
Mild asthma (n = 13) |
Moderate-to-severe asthma (n = 149) |
All (n = 162) |
||
| Patients who purchased SABA without a prescription in the past 12 months, n (%) | |||||||
| No | 244 (81.1) | 27 (84.4) | 83 (80.6) | 110 (81.5) | 13 (100) | 118 (79.2) | 131 (80.9) |
| Yes | 40 (13.3) | 1 (3.1) | 7 (6.8) | 8 (5.9) | 0 (0) | 31 (20.8) | 31 (19.1) |
| Unknown | 17 (5.6) | 4 (12.5) | 13 (12.6) | 17 (12.6) | 0 (0) | 0 (0) | 0 (0) |
| Number of SABA canisters or inhalers purchased without prescriptions in the past 12 months, n (%) | |||||||
| 1–2 | 15 (37.5) | 1 (100) | 3 (42.9) | 4 (50) | NA | 11 (35.5) | 11 (35.5) |
| 3–5 | 13 (32.5) | 0 (0) | 2 (28.6) | 2 (25) | NA | 10 (32.3) | 10 (32.3) |
| 6–9 | 2 (5) | 0 (0) | 0 (0) | 0 (0) | NA | 2 (6.5) | 2 (6.5) |
| 10–12 | 4 (10) | 0 (0) | 0 (0) | 0 (0) | NA | 4 (12.9) | 4 (12.9) |
| ≥ 13 | 2 (5) | 0 (0) | 1 (14.3) | 1 (12.5) | NA | 1 (3.2) | 1 (3.2) |
| Not applicablea | 4 (10) | 0 (0) | 1 (14.3) | 1 (12.5) | NA | 3 (9.7) | 3 (9.7) |
a“Not applicable” could be selected in the eCRF when patients purchased non-canister forms of SABA (e.g., oral, or nebulized SABA) without a prescription
Prescriber type was not recorded for 2 patients each in mild asthma and moderate-to-severe asthma group
Abbreviations: NA not available, OTC over the counter, SABA short-acting β2-agonist, SABINA SABA use IN Asthma, eCRF electronic case report form